- Home
- MYGN vs BFST Comparison
MYGN vs BFST Comparison
Compare MYGN & BFST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYGN
- BFST
- Stock Information
- Founded
- MYGN 1991
- BFST 2006
- Country
- MYGN United States
- BFST United States
- Employees
- MYGN N/A
- BFST N/A
- Industry
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- BFST Major Banks
- Sector
- MYGN Health Care
- BFST Finance
- Exchange
- MYGN Nasdaq
- BFST Nasdaq
- Market Cap
- MYGN 642.0M
- BFST 722.6M
- IPO Year
- MYGN 1995
- BFST 2018
- Fundamental
- Price
- MYGN $7.40
- BFST $23.97
- Analyst Decision
- MYGN Hold
- BFST Strong Buy
- Analyst Count
- MYGN 13
- BFST 3
- Target Price
- MYGN $13.50
- BFST $30.00
- AVG Volume (30 Days)
- MYGN 1.3M
- BFST 81.3K
- Earning Date
- MYGN 11-06-2025
- BFST 10-23-2025
- Dividend Yield
- MYGN N/A
- BFST 2.26%
- EPS Growth
- MYGN N/A
- BFST 3.92
- EPS
- MYGN N/A
- BFST 2.51
- Revenue
- MYGN $832,900,000.00
- BFST $291,096,000.00
- Revenue This Year
- MYGN $0.17
- BFST $25.00
- Revenue Next Year
- MYGN $6.19
- BFST $17.32
- P/E Ratio
- MYGN N/A
- BFST $9.86
- Revenue Growth
- MYGN 3.83
- BFST 17.48
- 52 Week Low
- MYGN $3.76
- BFST $20.07
- 52 Week High
- MYGN $29.30
- BFST $30.30
- Technical
- Relative Strength Index (RSI)
- MYGN 66.01
- BFST 40.94
- Support Level
- MYGN $7.13
- BFST $23.76
- Resistance Level
- MYGN $7.80
- BFST $24.94
- Average True Range (ATR)
- MYGN 0.44
- BFST 0.55
- MACD
- MYGN 0.04
- BFST -0.14
- Stochastic Oscillator
- MYGN 78.61
- BFST 9.59
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.
About BFST Business First Bancshares Inc.
Business First Bancshares Inc is a bank holding company. The company's services include personal and commercial banking, treasury management, and wealth solutions. It provides a range of financial services to small-to-midsized businesses and professionals. The company generates majority of its revenues from interest income on loans, customer service and loan fees, and interest income from securities.